Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ONCT-534 |
Synonyms | |
Therapy Description |
ONCT-534 is small molecule that binds to the AR N-terminal domain and induces degradation of AR, potentially resulting in decreased downstream signaling and reduced tumor growth (Mol Cancer Ther (2021) 20 (12_Supplement): LBA016). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ONCT-534 | ONCT534|ONCT 534|GTx-534|GTx534|GTx 534|UT-34 | Hormone - Anti-androgens 54 | ONCT-534 is small molecule that binds to the AR N-terminal domain and induces degradation of AR, potentially resulting in decreased downstream signaling and reduced tumor growth (Mol Cancer Ther (2021) 20 (12_Supplement): LBA016). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05917470 | Phase Ib/II | ONCT-534 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | Terminated | USA | GBR | 0 |